Unknown

Dataset Information

0

Patient preferences for first-line treatment of classical Hodgkin lymphoma: a US survey and discrete choice experiment.


ABSTRACT: A cross-sectional online survey, including a discrete choice experiment (DCE), was used to investigate first-line treatment preferences in patients with classical Hodgkin lymphoma (cHL) in the United States; 141 patients (median age 35.0 years) participated. In the DCE, risk of progression at 2 years (progression free survival) had the highest relative importance to patients (31.3%) when considering first-line treatments, followed by 2-year overall survival (OS; 26.9%), on-treatment pulmonary toxicity (23.3%), and on-treatment peripheral neuropathy (18.5%). Marginal rate of substitution analyses demonstrated that a 0.44% and 0.09% increase in 2-year OS was required for patients to accept a 1% increase in the risk of disease progression at 2 years and peripheral neuropathy, respectively. A 2.6% increase in 2-year OS was needed to accept a 7% rather than a 2% risk of pulmonary toxicity. In summary, patients with cHL rated survival attributes as more important than drug-related toxicity when considering first-line treatments.

SUBMITTER: Khan N 

PROVIDER: S-EPMC9175565 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

Patient preferences for first-line treatment of classical Hodgkin lymphoma: a US survey and discrete choice experiment.

Khan Niloufer N   Feliciano Joseph J   Müller Kerstin K   He Mary M   Tao Rei R   Korol Ellen E   Dalal Mehul M   Rebeira Mayvis M   Matasar Matthew M  

Leukemia & lymphoma 20200720 11


A cross-sectional online survey, including a discrete choice experiment (DCE), was used to investigate first-line treatment preferences in patients with classical Hodgkin lymphoma (cHL) in the United States; 141 patients (median age 35.0 years) participated. In the DCE, risk of progression at 2 years (progression free survival) had the highest relative importance to patients (31.3%) when considering first-line treatments, followed by 2-year overall survival (OS; 26.9%), on-treatment pulmonary to  ...[more]

Similar Datasets

| S-EPMC6585631 | biostudies-literature
| S-EPMC8274907 | biostudies-literature
| S-EPMC6439857 | biostudies-literature
| S-EPMC6858184 | biostudies-literature
| S-EPMC11877894 | biostudies-literature
| S-EPMC9693901 | biostudies-literature
| S-EPMC2440927 | biostudies-other
| S-EPMC2844026 | biostudies-other
| S-EPMC8357669 | biostudies-literature
| S-EPMC9850164 | biostudies-literature